Literature DB >> 12485328

Cytomegalovirus periodontal presence is associated with subgingival Dialister pneumosintes and alveolar bone loss.

J Slots1, C Sugar, J J Kamma.   

Abstract

Destructive periodontal disease is associated with human cytomegalovirus (HCMV), Epstein-Barr type 1 virus (EBV-1) and other members of the Herpesviridae family as well as with various gram-negative anaerobic bacteria, including the Dialister pneumosintes species. This study aimed to determine possible interrelationships between periodontal HCMV, EBV-1, herpes simplex virus and D. pneumosintes, and relate the microbiological findings to periodontitis clinical status. Sixteen subjects each contributed paper point samples from two progressing and two stable periodontitis lesions, as determined by ongoing loss of probing attachment. Polymerase chain reaction methodology was used to identify the study herpesviruses and D. pneumosintes. Chi-squared tests, Fisher exact tests and multivariate logistic regression were employed to identify statistical associations among herpesviruses, bacteria and clinical variables. HCMV, and no other virus or combination of viruses, was positively associated with the presence of D. pneumosintes, and the relationship was specific for individual periodontitis sites with no detectable subject effect. D. pneumosintes was in turn positively associated with periodontal pocket depth and disease-active periodontitis. When the average percentage of alveolar bone loss in all teeth was treated as a response, HCMV remained significant even after D. pneumosintes was included in the model, suggesting that both HCMV and D. pneumosintes affected bone loss or, alternatively, HCMV affected factors not studied that themselves can induce bone loss. We hypothesize that periodontal HCMV sets the stage for subgingival proliferation of D. pneumosintes and subsequent periodontal disease progression. Studies on herpesviral-bacterial interactions may hold great promise for delineating important etio-pathogenic aspects of destructive periodontal disease.

Entities:  

Mesh:

Year:  2002        PMID: 12485328     DOI: 10.1034/j.1399-302x.2002.170606.x

Source DB:  PubMed          Journal:  Oral Microbiol Immunol        ISSN: 0902-0055


  7 in total

1.  Infection frequency of Epstein-Barr virus in subgingival samples from patients with different periodontal status and its correlation with clinical parameters.

Authors:  Yan-min Wu; Jie Yan; Li-li Chen; Wei-lian Sun; Zhi-yuan Gu
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

2.  Correlation between infections with different genotypes of human cytomegalovirus and Epstein-Barr virus in subgingival samples and periodontal status of patients.

Authors:  Yan-Min Wu; Jie Yan; David M Ojcius; Li-Li Chen; Zhi-Yuan Gu; Jian-Ping Pan
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

Review 3.  The Human Oral Microbiome in Health and Disease: From Sequences to Ecosystems.

Authors:  Jesse R Willis; Toni Gabaldón
Journal:  Microorganisms       Date:  2020-02-23

4.  Quantification of Epstein-Barr Virus and Human Cytomegalovirus in Chronic Periodontal Patients.

Authors:  Hengameh Khosropanah; Maryam Karandish; Mazyar Ziaeyan; Marzieh Jamalidoust
Journal:  Jundishapur J Microbiol       Date:  2015-06-30       Impact factor: 0.747

Review 5.  Herpesviral-bacterial interactions in periodontal diseases.

Authors:  Jørgen Slots
Journal:  Periodontol 2000       Date:  2010-02       Impact factor: 7.589

6.  Gut Microbiome Reveals Specific Dysbiosis in Primary Osteoporosis.

Authors:  Zhiming Xu; Zheng Xie; Jianguang Sun; Shilei Huang; Yangyang Chen; Chengxiang Li; Xing Sun; Bicheng Xia; Lingyang Tian; Caijuan Guo; Feng Li; Guofu Pi
Journal:  Front Cell Infect Microbiol       Date:  2020-04-21       Impact factor: 5.293

7.  Prevalence of herpesviruses in periodontal disease of the North Indian population: A pilot study.

Authors:  Rameshwari Singhal; Amita Jain; Pavitra Rastogi
Journal:  J Indian Soc Periodontol       Date:  2020-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.